1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Immunoassay Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Immunoassay Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Immunoassay Market Analysis and Forecast, by Product
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product, 2017–2031
        6.3.1. Analyzers
        6.3.2. Consumables
    6.4. Market Attractiveness, by Product
7. Global Immunoassay Market Analysis and Forecast, by Technology
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Technology, 2017–2031
        7.3.1. Chemiluminescence Immunoassay (CLIA)
        7.3.2. Enzyme-linked Immunoassay (ELISA)
        7.3.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        7.3.4. Radioimmunoassay (RIA)
        7.3.5. Others
        7.3.6. 7.4 Market Attractiveness, by Technology
8. Global Immunoassay Market Analysis and Forecast, by Application
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017–2031
        8.3.1. Infectious Disease
        8.3.2. Endocrinology
        8.3.3. Oncology
        8.3.4. Cardiology
        8.3.5. Orthopedics
        8.3.6. Others
    8.4. Market Attractiveness, by Application
9. Global Immunoassay Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017–2031
        9.3.1. Hospitals & Diagnostic Laboratories
        9.3.2. Blood Banks
        9.3.3. Others
    9.4. Market Attractiveness, by End-user
10. Global Immunoassay Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017–2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Immunoassay Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product, 2017–2031
        11.2.1. Analyzers
        11.2.2. Consumables
    11.3. Market Attractiveness, by Product
    11.4. Market Value Forecast, by Technology, 2017–2031
        11.4.1. Chemiluminescence Immunoassay (CLIA)
        11.4.2. Enzyme-linked Immunoassay (ELISA)
        11.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        11.4.4. Radioimmunoassay (RIA)
        11.4.5. Others
    11.5. Market Attractiveness, by Technology
    11.6. Market Value Forecast, by Application, 2017–2031
        11.6.1. Infectious Disease
        11.6.2. Endocrinology
        11.6.3. Oncology
        11.6.4. Cardiology
        11.6.5. Orthopedics
        11.6.6. Others
    11.7. Market Attractiveness, by Application
    11.8. Market Value Forecast, by End-user, 2017–2031
        11.8.1. Hospitals & Diagnostic Laboratories
        11.8.2. Blood Banks
        11.8.3. Others
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Product
        11.11.2. By Technology
        11.11.3. By Application
        11.11.4. By End-user
        11.11.5. By Country
12. Europe Immunoassay Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product, 2017–2031
        12.2.1. Analyzers
        12.2.2. Consumables
    12.3. Market Attractiveness, by Product
    12.4. Market Value Forecast, by Technology, 2017–2031
        12.4.1. Chemiluminescence Immunoassay (CLIA)
        12.4.2. Enzyme-linked Immunoassay (ELISA)
        12.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        12.4.4. Radioimmunoassay (RIA)
        12.4.5. Others
    12.5. Market Attractiveness, by Technology
    12.6. Market Value Forecast, by Application, 2017–2031
        12.6.1. Infectious Disease
        12.6.2. Endocrinology
        12.6.3. Oncology
        12.6.4. Cardiology
        12.6.5. Orthopedics
        12.6.6. Others
    12.7. Market Attractiveness, by Application
    12.8. Market Value Forecast, by End-user, 2017–2031
        12.8.1. Hospitals & Diagnostic Laboratories
        12.8.2. Blood Banks
        12.8.3. Others
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Product
        12.11.2. By Technology
        12.11.3. By Application
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Immunoassay Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product, 2017–2031
        13.2.1. Analyzers
        13.2.2. Consumables
    13.3. Market Attractiveness, by Product
    13.4. Market Value Forecast, by Technology, 2017–2031
        13.4.1. Chemiluminescence Immunoassay (CLIA)
        13.4.2. Enzyme-linked Immunoassay (ELISA)
        13.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        13.4.4. Radioimmunoassay (RIA)
        13.4.5. Others
    13.5. Market Attractiveness, by Technology
    13.6. Market Value Forecast, by Application, 2017–2031
        13.6.1. Infectious Disease
        13.6.2. Endocrinology
        13.6.3. Oncology
        13.6.4. Cardiology
        13.6.5. Orthopedics
        13.6.6. Others
    13.7. Market Attractiveness, by Application
    13.8. Market Value Forecast, by End-user, 2017–2031
        13.8.1. Hospitals & Diagnostic Laboratories
        13.8.2. Blood Banks
        13.8.3. Others
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Product
        13.11.2. By Technology
        13.11.3. By Application
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Immunoassay Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product, 2017–2031
        14.2.1. Analyzers
        14.2.2. Consumables
    14.3. Market Attractiveness, by Product
    14.4. Market Value Forecast, by Technology, 2017–2031
        14.4.1. Chemiluminescence Immunoassay (CLIA)
        14.4.2. Enzyme-linked Immunoassay (ELISA)
        14.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        14.4.4. Radioimmunoassay (RIA)
        14.4.5. Others
    14.5. Market Attractiveness, by Technology
    14.6. Market Value Forecast, by Application, 2017–2031
        14.6.1. Infectious Disease
        14.6.2. Endocrinology
        14.6.3. Oncology
        14.6.4. Cardiology
        14.6.5. Orthopedics
        14.6.6. Others
    14.7. Market Attractiveness, by Application
    14.8. Market Value Forecast, by End-user, 2017–2031
        14.8.1. Hospitals & Diagnostic Laboratories
        14.8.2. Blood Banks
        14.8.3. Others
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Product
        14.11.2. By Technology
        14.11.3. By Application
        14.11.4. By End-user
        14.11.5. By Country/Sub-region
15. Middle East & Africa Immunoassay Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Product, 2017–2031
        15.2.1. Analyzers
        15.2.2. Consumables
    15.3. Market Attractiveness, by Product
    15.4. Market Value Forecast, by Technology, 2017–2031
        15.4.1. Chemiluminescence Immunoassay (CLIA)
        15.4.2. Enzyme-linked Immunoassay (ELISA)
        15.4.3. Enzyme-linked Immunofluorescent Assay (ELFA)
        15.4.4. Radioimmunoassay (RIA)
        15.4.5. Others
    15.5. Market Attractiveness, by Technology
    15.6. Market Value Forecast, by Application, 2017–2031
        15.6.1. Infectious Disease
        15.6.2. Endocrinology
        15.6.3. Oncology
        15.6.4. Cardiology
        15.6.5. Orthopedics
        15.6.6. Others
    15.7. Market Attractiveness, by Application
    15.8. Market Value Forecast, by End-user, 2017–2031
        15.8.1. Hospitals & Diagnostic Laboratories
        15.8.2. Blood Banks
        15.8.3. Others
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Product
        15.11.2. By Technology
        15.11.3. By Application
        15.11.4. By End-user
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. F. Hoffmann-La Roche Ltd.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Danaher Corporation
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Abbott Laboratories
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Siemens Healthineers (Siemens AG)
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. DiaSorin S.p.A.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Sysmex Corporation
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. bioMerieux SA
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Ortho Clinical Diagnostics
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Thermo Fisher Scientific, Inc.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Becton, Dickinson and Company
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Merck kGaA
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			